Tenaya Therapeutics, Inc.
TNYA
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsuffā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.74
Price-1.29%
-$0.01
1Y
Price
Market Cap
$160.644m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$225k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$83.005m
+15.2%
1y CAGR+8.4%
3y CAGR-11.2%
5y CAGREPS
-$0.47
+40.5%
1y CAGR+33.9%
3y CAGR+9.6%
5y CAGRBook Value
$106.189m
$135.070m
Assets$28.881m
Liabilities$10.117m
DebtDebt to Assets
7.5%
-0.1x
Debt to EBITDAFree Cash Flow
-$64.632m
+19.7%
1y CAGR+16.2%
3y CAGR+0.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company